18F-FDG PET/CT in diagnosis of retroperitoneal fibrosis
10.13929/j.1672-8475.201710003
- VernacularTitle:18F-FDG PET/CT诊断腹膜后纤维化
- Author:
Lijuan DI
1
;
Jianhua ZHANG
;
Yan FAN
;
Guangyu ZHAO
;
Yonggang CUI
;
Hongjie LIU
;
Rongfu WANG
Author Information
1. 北京大学第一医院核医学科
- Keywords:
Retroperitoneal fibrosis;
Positron-emission tomography;
Tomography,X-ray computed;
Activity
- From:
Chinese Journal of Interventional Imaging and Therapy
2018;15(2):90-94
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of 18F-FDG PET/CT in diagnosis of retroperitoneal fibrosis (RPF).Methods Totally 12 RPF patients underwent 18 F-FDG PET/CT scanning,and the characteristics of metabolic activity,distribution of retroperitoneal lesions and maximum standardized uptake value (SUVmax) were analyzed retrospectively.Results Among 12 patients,7 were initial evaluation patients,5 were post-treatment patients.Of 7 initial evaluation patients,there were 4 patients with secondary RPF,including prostate carcinoma,breast cancer and IgG4-related disease.Retroperitoneal mass isodense with muscle surrounding the abdominal aorta or the iliac arteries were found in 12 patients,and ureteral involvement were found in 11 paients (11/12,91.67％).SUVmax in initial evaluation patients (4.21±1.76) was higher than that in patients after treatment (1.46±0.25,P＜0.05).According to PET/CT,3 idiopathic RPF patients as initial evaluation with high metabolic activity lesions received immunosuppressive therapy including corticosteroids and tamoxifen,and 4 secondary RPF patients with high metabolic activity lesions received treatment based on causes.Among 5 post-treatment patients,3 continued to accept current corticosteroids maintenance dose,while 2 did not receive any other treatment.Conclusion PET/CT may be used to evaluate the activity and extension of lesions in patients with RPF.
